|
Ulcerative Colitis
|
0.640 |
AlteredExpression
|
disease |
BEFREE |
CCL20 mRNA and protein were severalfold increased in involved CD and UC but not in non-IBD colitis.
|
14997037 |
2004 |
|
Ulcerative Colitis
|
0.640 |
Biomarker
|
disease |
CTD_human |
Supporting these findings, results from a 3-month follow-up study revealed that the UC groups treated with 5-aminosalicylic acid and glucocorticoid exhibited dramatic decreases of CCL20 mRNA in PBMCs, accompanied by ameliorated disease states.
|
16306769 |
2005 |
|
Ulcerative Colitis
|
0.640 |
Biomarker
|
disease |
BEFREE |
CCL20 and CCR6 mRNA abundances were increased during active inflammation (CCL20 5.4-fold in ulcerative colitis and 4.2-fold in Crohn's disease; CCR6 1.8 and 2.0, respectively).
|
26536229 |
2015 |
|
Ulcerative Colitis
|
0.640 |
Biomarker
|
disease |
BEFREE |
CCL20 may play a significant role in local damage and pathological changes in UC and may serve as a potential target for therapy.
|
23008075 |
2012 |
|
Ulcerative Colitis
|
0.640 |
Biomarker
|
disease |
BEFREE |
The present study assessed the mRNA expression levels of Th17 effector cytokines (IL17A, IL17F, IL21, IL22 and IL26) and genes involved in differentiation (IL6, IL1B, TGFB1, IL23A and STAT3) and recruitment of Th17 cells (CCR6 and CCL20) by quantitative real-time PCR analysis of colonic and ileal biopsies from 22 healthy control subjects, 26 patients with Crohn's disease (CD) and 12 patients with ulcerative colitis (UC).
|
21144017 |
2010 |
|
Ulcerative Colitis
|
0.640 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Ulcerative Colitis
|
0.640 |
Therapeutic
|
disease |
RGD |
The results showed that baicalin simultaneously down-regulated the expression of MIF, the quantity of MΦs and the amount of MΦ-related cytokines, including macrophage chemotactic factor-1 (MCP-1, CCL2) and macrophage inflammatory protein-3α (MIP-3α, CCL20), in rats with UC.
|
21887805 |
2012 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Since the microenvironment of breast cancer includes CCL20 chemokine, the purpose of this study was to determine whether CCL20 modulates the physiology of healthy breast epithelial cells in areas adjacent to the tumor.
|
23460117 |
2013 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer.
|
30930637 |
2019 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells.
|
28851919 |
2017 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CCL20 can be a novel predictive marker for taxane response, and the blockade of CCL20 or its downstream pathway might reverse the taxane resistance in breast cancer patients.
|
30052635 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)).
|
24937182 |
2014 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)).
|
24937182 |
2014 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Since the microenvironment of breast cancer includes CCL20 chemokine, the purpose of this study was to determine whether CCL20 modulates the physiology of healthy breast epithelial cells in areas adjacent to the tumor.
|
23460117 |
2013 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells.
|
28851919 |
2017 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CCL20 can be a novel predictive marker for taxane response, and the blockade of CCL20 or its downstream pathway might reverse the taxane resistance in breast cancer patients.
|
30052635 |
2018 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer.
|
30930637 |
2019 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Malignant neoplasm of pancreas
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
CCL20/CCR6 expression profile in pancreatic cancer.
|
20459729 |
2010 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
|
28188806 |
2017 |
|
Alloxan Diabetes
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes.
|
21340626 |
2011 |
|
Malignant tumor of colon
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Diabetes Mellitus, Experimental
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes.
|
21340626 |
2011 |